Distinct transcriptomic programs and proximal AKT activation associated with AKT1 E17K and PIK3CA hotspot mutations in HR-positive/HER2-negative breast cancer Running title: Molecular differences between AKT1- and PIK3CA-mutant breast cancer
This study demonstrates that while AKT1 E17K and PIK3CA hotspot mutations in HR-positive/HER2-negative breast cancer are mutually exclusive and often grouped together, they drive distinct transcriptomic programs and exhibit preferential proximal AKT activation without uniform downstream mTOR activation, indicating they represent non-equivalent molecular states.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside the cells of the human body, a complex network of chemical signals acts as a central command system, telling cells when to grow, when to divide, and when to stop. In many cases of breast cancer, this system gets stuck in the "on" position, driving uncontrolled growth. Two specific parts of this network, known as the PI3K and AKT pathways, are frequently involved. Scientists have long known that mutations in the genes controlling these pathways are common drivers of the disease. For years, medical treatments have grouped these mutations together, assuming that a glitch in the PI3K gene and a glitch in the AKT gene produce the same biological result, making them interchangeable targets for therapy. However, this assumption treats two different types of errors as if they were identical, potentially overlooking subtle but critical differences in how the cancer behaves.
A team of researchers set out to test whether these two types of mutations truly create the same molecular environment within a tumor. They focused on a specific, common form of breast cancer that is driven by hormones but does not respond to the HER2 protein. Using data from thousands of patient tumors collected in two massive, independent scientific databases, they compared tumors carrying the AKT mutation against those carrying the PIK3CA mutation. The study revealed that while these mutations often appear in similar types of patients, they do not produce the same internal state. The researchers found that tumors with the AKT mutation activate a distinct set of genetic programs and show a specific pattern of chemical signaling that is different from tumors with the PIK3CA mutation.
The investigation began by sorting through genetic records from over 2,400 tumors in one database and more than 800 in another. The researchers looked for specific, recurring changes in the DNA of the AKT1 and PIK3CA genes. They discovered that these mutations are largely mutually exclusive, meaning a tumor usually has one or the other, but rarely both. In the larger group of patients, the AKT mutation appeared in about 3 percent of cases, while the PIK3CA mutation was found in roughly 30 percent. This confirmed that while both are important, they affect different subsets of patients. The team then narrowed their focus to the hormone-positive, HER2-negative tumors, which are the most relevant for the treatments currently in use, to see if the molecular differences held true in this specific group.
When the researchers examined the activity of genes inside these tumors, they found clear distinctions. In the tumors with the AKT mutation, the cells showed higher activity in pathways related to cell division and the processing of sugar for energy. They also showed increased activity in the machinery that moves proteins within the cell and separates chromosomes during division. Conversely, these same tumors showed lower activity in the systems that normally help build proteins and clean up genetic errors. These patterns were not just random noise; they were consistent across both databases, suggesting that the AKT mutation drives a unique biological program that is distinct from the one driven by the PIK3CA mutation.
To understand what was happening at the protein level, the researchers looked at a snapshot of the chemical signals inside the tumors. They found that in the AKT-mutated tumors, the AKT protein itself was highly activated, with specific chemical tags attached to it that turn it on. This activation was significantly stronger than in the PIK3CA-mutated tumors. However, a crucial finding emerged when they looked at what happened next. Despite the strong activation of the AKT protein, the downstream effects were not uniformly stronger. The proteins that usually receive the signal from AKT to tell the cell to grow did not show a corresponding increase in activity. This suggests that the AKT mutation creates a very specific, localized surge in signaling that does not necessarily translate into a massive, global increase in cell growth commands throughout the entire network.
The study also examined whether other genetic factors, such as the overall number of mutations in a tumor or large-scale changes in the DNA structure, could explain these differences. The researchers found that the tumors were quite similar in these broad genomic aspects, indicating that the distinct behaviors they observed were truly due to the specific type of mutation present, not just a general difference in the tumor's genetic chaos. They also looked at the immune system's presence within the tumors and the patients' survival rates, but the data did not show a clear, consistent pattern that could be linked directly to the mutation type across both groups of patients.
These findings challenge the idea that all mutations in this signaling pathway are the same. The research suggests that while both mutations activate the same general pathway, they do so in different ways, leading to different internal states within the cancer cell. The AKT mutation appears to create a specific profile of gene activity and protein signaling that is not simply a stronger version of the PIK3CA mutation. This distinction is important because it implies that grouping these mutations together for treatment purposes might be too broad. The authors conclude that while the current therapies may work for both, the underlying biology is different, and future treatments may need to be tailored to these specific molecular differences. The study does not yet prove that one mutation responds better to a specific drug than the other, but it provides a clear biological reason to investigate them separately.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.